North American Vaccine Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : North American Vaccine

NVX 1.140

-16.2%

Jan 16 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Cacaito who wrote (290)	2/13/1998 8:11:00 AM
From: Don W Stone	Read Replies (1) of 507

Cacaito: Here are a few comments on NVX's meningitis activity. 1)NVX is developing a conjugate vaccine against Groups A, B and C meningitis for adults and infants. 2)They are co-developers with Connaught on the meningitis C vaccine. Connaught is making milestone payments to NVX to the tune of some $40 to $50 million dollars. So far they have paid in some $12 million to NVX. It is NVX's advanced conjugate technology that helped foster this deal a couple of years ago. You will have to explain to me what type of meningitis you are talking about in your post. I am a laymen. As to the market and fitting this product into a schedule? I'll leave that up to the CDC/ACIP. If NVX has their way it will be part of their "giant coctail" someday. DTaP-IPV-Hib-MenA/B/C. By coincidence one of the Providence Journal headline articles today is "Officials suspect meningitis in boy's sudden death". This is the second death and the third case recently in the same town of Woonsocket, R.I.. They are planning their second mass innoculation of some 20,000 people. Always good to here from you. thanks.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next